Nanotechnology Now - News Story: Celator(R) Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing

Home > News > Celator(R) Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing

June 4th, 2007

Celator(R) Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing

Abstract:
Celator Pharmaceuticals announced positive safety and efficacy results from its Phase I study of CPX-1 (Irinotecan HCI:Floxuridine), Liposome Injection in patients with heavily pre-treated, advanced solid tumors. Results were presented yesterday in a poster presentation at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

CPX-1 is a combination therapy including irinotecan HCI and floxuridine, two approved and well known drug agents to treat cancer. The formulation of CPX-1 was developed based on ratiometric dosing using Celator's CombiPlex(TM) technology platform, a proprietary technology that identifies the optimal ratio of drugs to use in combination therapies and then incorporates an advanced nanoparticle delivery system to maintain those optimal ratios when drugs are administered and metabolized in patients. Pending regulatory approval, CPX-1 would be the first commercially-available combination therapy based on Celator's ratiometric dosing drug development platform.

Source:
earthtimes.org

Bookmark: